The stock market was experiencing a frothy Friday on the last trading day of the week, but 23andMe Holding (NASDAQ: ME) was a bit of a wallflower at the party. As of 1:30 p.m. ET , the genetic testing and research specialist's shares were up only incrementally, at a rate well behind the S&P 500 index's 1.7% gain. For 23andMe's fourth quarter of fiscal 2022, the company recorded just under $101 million in revenue, which was 14% higher than the same period of the previous year.
Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services expected in FY2023Webcast today, May 26, 2022, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the hu
Quarterhill Inc. ("Quarterhill" or "the Company") (TSX: QTRH) (OTCQX: QTRHF) announces that John Karnes has been appointed Chief Financial Officer ("CFO") of the Company effective June 6, 2022. Mr. Karnes will replace Steve Thompson, Wi-LAN Inc.'s CFO, who is currently interim-CFO of Quarterhill.